C4 Therapeutics Statistics

Total Valuation

C4 Therapeutics has a market cap or net worth of $212.47 million. The enterprise value is -$4.83 million.

Market Cap	212.47M
Enterprise Value	-4.83M

Important Dates

The next estimated earnings date is Tuesday, March 4, 2025, before market open.

Earnings Date	Mar 4, 2025
Ex-Dividend Date	n/a

Share Statistics

C4 Therapeutics has 70.59 million shares outstanding. The number of shares has increased by 31.51% in one year.

Current Share Class	70.59M
Shares Outstanding	70.59M
Shares Change (YoY)	+31.51%
Shares Change (QoQ)	+1.19%
Owned by Insiders (%)	2.66%
Owned by Institutions (%)	75.61%
Float	46.85M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.77
Forward PS	13.76
PB Ratio	0.88
P/TBV Ratio	0.88
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.31, with a Debt / Equity ratio of 0.28.

Current Ratio	6.31
Quick Ratio	6.14
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -46.00% and return on invested capital (ROIC) is -24.44%.

Return on Equity (ROE)	-46.00%
Return on Assets (ROA)	-20.61%
Return on Invested Capital (ROIC)	-24.44%
Return on Capital Employed (ROCE)	-35.13%
Revenue Per Employee	$232,193
Profits Per Employee	-$727,566
Employee Count	145
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

In the past 12 months, C4 Therapeutics has paid $277,000 in taxes.

Income Tax	277,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -60.29% in the last 52 weeks. The beta is 2.96, so C4 Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	2.96
52-Week Price Change	-60.29%
50-Day Moving Average	3.71
200-Day Moving Average	5.12
Relative Strength Index (RSI)	33.55
Average Volume (20 Days)	1,808,481

Short Selling Information

The latest short interest is 7.40 million, so 10.48% of the outstanding shares have been sold short.

Short Interest	7.40M
Short Previous Month	9.28M
Short % of Shares Out	10.48%
Short % of Float	15.80%
Short Ratio (days to cover)	3.78

Income Statement

In the last 12 months, C4 Therapeutics had revenue of $33.67 million and -$105.50 million in losses. Loss per share was -$1.63.

Revenue	33.67M
Gross Profit	-74.85M
Operating Income	-116.90M
Pretax Income	-106.59M
Net Income	-105.50M
EBITDA	-115.13M
EBIT	-116.90M
Loss Per Share	-$1.63

Full Income Statement

Balance Sheet

The company has $255.64 million in cash and $67.10 million in debt, giving a net cash position of $217.31 million or $3.08 per share.

Cash & Cash Equivalents	255.64M
Total Debt	67.10M
Net Cash	217.31M
Net Cash Per Share	$3.08
Equity (Book Value)	242.66M
Book Value Per Share	3.44
Working Capital	229.94M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$71.23 million and capital expenditures -$341,000, giving a free cash flow of -$71.58 million.

Operating Cash Flow	-71.23M
Capital Expenditures	-341,000
Free Cash Flow	-71.58M
FCF Per Share	-$1.01

Full Cash Flow Statement

Margins

Gross Margin	-222.31%
Operating Margin	-347.20%
Pretax Margin	-312.52%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

C4 Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-31.51%
Shareholder Yield	-31.51%
Earnings Yield	-49.65%
FCF Yield	-33.69%

Analyst Forecast

The average price target for C4 Therapeutics is $11.60, which is 285.38% higher than the current price. The consensus rating is "Buy".

Price Target	$11.60
Price Target Difference	285.38%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	99.51%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

C4 Therapeutics has an Altman Z-Score of -0.8 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.8
Piotroski F-Score	3